Seventh of the "ASCO Direct™ China" webinar: Advanced Esophageal Cancer Therapy

About this event

Webinar Date:

  • China Time: Saturday, Aug 7th, 9:00 AM
  • US EST Time: Friday, Aug 6th, 9:00 PM
  • US PST Time: Friday, Aug 6th, 6:00 PM

Language: English, with Chinese simultaneous translation

Venue: Live Zoom Webinar

Webinar Agenda

Chairs:

US Co-Chairs:

  • Dr. George Fisher, Stanford University

China Co-Chairs:

  • Dr. Ruihua Xu, Sun Yat-sen University Cancer Center

Presentations:

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC) (ASCO Abstract #4000)

  • Dr. Hui-yan Luo, Sun Yat-sen University Cancer Center

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study (ASCO Abstract #LBA 4001)

  • Dr. Ian Chau, The Royal Marsden Hospital

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study (ASCO Abstract #168)

  • Dr. Ken Kato , National Cancer Center Hospital

Finding First-Line Chemoimmunotherapy for Esophageal Cancer

  • Dr. Zhihao Lu, Peking University Cancer Hospital

Panel Discussion

  • Dr. Ruihua Xu, Sun Yat-sen University Cancer Center
  • Dr. George Fisher, Stanford University
  • Dr. Ian Chau, The Royal Marsden
  • Dr. Ken Kato , National Cancer Center Hospital
  • Dr. Hui-yan Luo, Sun Yat-sen University Cancer Center
  • Dr. Zhihao Lu, Peking University Cancer Hospital

Speakers and Panelists Bio

Dr. George Fisher, Stanford University

Dr. George Fisher is a Professor of Medical Oncology at Stanford University where he specializes in gastrointestinal cancers. He received his PhD in Cancer Biology and did all of his medical training at Stanford.

Dr. Fisher is co-chair of the GI Committee for ECOG-ACRIN and serves on the NCI GI Steering Committee which is responsible for approving all randomized GI cancer trials within the National Cancer Trials Network (NCTN). His primary interest is in the design and conduct of therapeutic trials but he also collaborates with colleague in molecular biomarker and imaging research.

Dr. Ruihua Xu, Sun Yat-sen University Cancer Center

Prof. Ruihua Xu specializes in GI medical oncology, mainly engaged in the development of novel drugs and individualized treatment for GI cancer. Several of his innovative achievements have international leading position, including research of metastasis of GI cancer, chemotherapy drug resistance mechanism and optimization of clinical management. The 5-year survival rate of his patients leads international advanced level. Dr. Xu has performed a series of research into GI cancer individualized treatment and conducted several global or domestic multi-center clinical trials, and these achievements significantly prolong overall survival time of gastric or colorectal cancer patients. The main academic achievements of Prof. Xu can be summarized into the following three aspects:

1. Pioneering new therapeutic regimens, amending international guidelines and revolutionizing the treatments of gastrointestinal cancer, both in China and internationally.

2. Breakthroughs in cancer diagnosis: using molecular biomarkers to formulate novel strategies that have significantly improve early cancer diagnosis and treatment efficacy prediction

3. Innovations tackling issues of drug resistance and tumor metastasis, discovered new pathway mechanisms, identified new therapeutic targets, improved the translational study of digestive system tumors in China, and promoted domestic clinical research of new drugs to an international level.

He has published 199 SCI papers (including 31 papers of IF score >10) in top international journals such as Nature Materials and Lancet Oncology as a corresponding author or first author. More importantly, these studies’ results were internationally recognized as impactful and have been used to improve the cancer diagnosis and treatment of 30 international guidelines and 106 English classic monographs Being nominated as a first accomplisher, he has won 2 prizes of the National Science and Technology Progress Award (2nd level) and 6 prizes of the provincial and ministerial awards (1st level), including the Chinese Medical Science and Technology Award, and more.

Dr. Hui-yan Luo, Sun Yat-sen University Cancer Center

Luo’s primary research interests include clinical and translational research in GI medical oncology, especially in early diagnosis by liquid biopsy, artificial intelligence (AI)-assisted diagnosis system and developing prognostic and predictive markers in patients with GI cancer

She has published more than 20 papers in peer reviewed Journals like Nature Materials, Lancet Oncology,Annals of Oncology, PNAS, Clinical Cancer research and presenting several abstracts to ASCO and ESMO meetings.

Dr. Ian Chau, The Royal Marsden

Dr Ian Chau holds the position of consultant medical oncologist within the Gastrointestinal and Lymphoma Units at Royal Marsden Hospital and Reader at the Institute of Cancer Research, London & Surrey, UK. He qualified from the United Medical & Dental Schools of Guy’s and St. Thomas’ Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital.

He is the chief or principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways. He serves or has served on American Society of Clinical Oncology (ASCO) Scientific Program Committee, ASCO Education Committee, European Society of Medical Oncology (ESMO) Congress Steering Committee, ESMO Asia Scientific Programme and Steering Committee, ESMO Educational Committee and UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups, He was the track leaders for Gastrointestinal (non-colorectal) Cancer for ASCO Annual Meeting Education Committee and ESMO Scientific Committee as well as Scientific Chairman for ESMO Asia Congress in 2019. He is on the Trial Management Groups and Trial Steering Groups of multiple national and global phase II-III gastrointestinal cancer and lymphoma trials.

He serves or has served on the UK National Institute of Health and Care Excellence (NICE) Clinical Guideline Development Group for non-Hodgkin’s Lymphoma, ASCO Expert Panel for the Management of Immunotherapy Toxicities Guideline and ESMO Clinical Practice Guidelines for Hepatocellular Carcinoma panel. He is the recipient of Swedish Society of GI Oncology Bengt Glimelius Award 2016, merit awards from ASCO Gastrointestinal Cancer Symposium, The Royal Society of Medicine Section of Oncology Clinical Prize, fellowships from the European School of Oncology and ASCO/AACR/FECS Clinical Cancer Research Workshop. He has given invited lectures in over 30 countries.

He has served on international drug development advisory boards and has peer review publications in the New England Journal of Medicine, The Lancet, The Lancet Oncology, Journal of Clinical Oncology and other leading oncology / biomedical journals.

Dr. Ken Kato , National Cancer Center Hospital

  • Chief, Department of Head and Neck, Esophageal Medical Oncology
  • Chief, Department of Gastrointestinal Medical Oncology
  • Chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office
  • National Cancer Center Hospital, Tokyo, Japan

RESEARCH INTEREST

  • Chemotherapy and chemoradiotherapy for upper-GI tumor
  • Multimodal treatment for esophageal cancer
  • Biobank and translational research

PROFESSIONAL EXPERIENCES

  • 2004-2006 Chief Resident, National Cancer Center Hospital, Tokyo
  • 2006-2012 Medical staff, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo
  • 2013-Present Chief, Biobank Translational Research Support Section, Clinical Research
  • Coordinating Section, Clinical Research Support Office
  • 2020-Present Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo
  • 2021-Present Chief, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo

PUBLICATIONS

  • 2019 Kato K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Sep 27.: S1470-2045(19)30626-6.
  • 2021 Sun JM, Kato K, et al. Pembrolizumab plus chemotherapy versus chemotherapy for first-line, advanced esophageal cancer: the randomized, placebo-controlled phase 3 KEYNOTE-590 study Lancet in press 2021
  • 2021 Kato K, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma Gastroenterology in press 2021

Dr. Zhihao Lu, Peking University Cancer Hospital

Prof. Zhihao Lu , Peking University Cancer Hospital Postdoctor of Oncology, Johns Hopkins Hospital, USAAssociate Chief Physician, Associate Professor and Master Supervisor of Department of Gastroenterology, Peking UniversityEditorial Director of Electronic Journal of Comprehensive Treatment of Tumor“CSCO” 35 under 35--young oncologist with the highest potentialYouth Member and Secretary of Nutrition and Support Therapy Committee, Chinese Anti Cancer AssociationYouth Member of Esophageal cancer Professional Committee, Chinese Anti Cancer AssociationMember of Drug Clinical Trial Professional Committee, Chinese Anti Cancer AssociationMainly engaged in the drug treatment and comprehensive treatment of gastrointestinal cancer, including chemotherapy, molecular targeted therapy and immunotherapy of advanced esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer and neuroendocrine tumors, etc.

Advanced Esophageal Cancer Therapy

ASCO Abstract #4000

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC)

ASCO Abstract #LBA 4001

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study

ASCO Abstract #168

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study


If you need to request a copy of the abstract, please send email to "webinars@eChinaHealth.com”.

Disclaimers: ASCO Licensing and eChinaHealth do not endorse any health care product, therapy, diagnostic test or device mentioned in this webinar.